Searchlight Pharma Announces Deal That Adds Divigel® To Its Canadian Portfolio
- Searchlight Pharma expands its women’s health portfolio by assuming Canadian distribution and promotional activites for Divigel® effective December 7th, 2018
- Divigel® is a prescription transdermal estrogen product approved and available in Canada that competes in the $17.4 million estrogen gel market in Canada
- Vertical Pharmaceuticals, LLC which holds the United States commercial rights has successfully driven Divigel® to be the #1 prescribed estrogen gel
MONTREAL, Nov. 28, 2018 /CNW Telbec/ – Searchlight Pharma Inc. (“Searchlight”) is pleased to announce the closing of a transaction whereby Searchlight will take over the Canadian commercial rights to Divigel®. As a result of the transaction, Searchlight will transition and assume distribution and promotional activities in Canada effective December 7th, 2018. Vertical Pharmaceuticals, LLC (“Vertical”) who has the market rights in the United States, will work closely with Searchlight to share its market leadership insights as Searchlight prepares to relaunch the brand in Canada. Financial terms of the transaction were not disclosed.
Divigel® (estradiol gel) 0.1% is a prescription, estrogen gel indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, that is applied once daily to a small area of the upper thigh. The product is supplied in a tiny, single-use sachet pack and is available in three doses of 0.1% estradiol: 0.25, 0.5 and 1.0 g/day, thereby offering convenient and flexible dosing. According to IQVIA CDH data, the Canadian market for prescription hormonal menopause treatments in Canada was valued at $118 million in 2017, and the estrogen gel market alone totaled $17.4 million.1 In the United States, Divigel® is the #1 prescribed estrogen gel.2
“We are pleased to conclude our fourth business development transaction in 2018, and to add an already-approved and marketed product that complements our existing range of products in women’s health, including Estragyn™ Vaginal Cream, Mona Lisa® IUDs, OesclimTDS®., Zestica Moisture™ and AmnioSense®blue,” said Mark Nawacki, President and CEO of Searchlight.” With Divigel® we expand our ability to offer an even wider range of therapeutic solutions that address women’s needs in managing menopause, and deepen our commitment to becoming the Canadian leader in women’s health. We are also excited to learn from our partners at Vertical, who have demonstrated impressive commercial traction in making Divigel® the #1 prescribed estrogen gel in the US, as we immediately begin preparations to relaunch the brand in Q1 2019.”
Divigel® (estradiol gel) 0.1%, at doses of 0.25, 0.5 and 1.0 g/day, is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause3. Each gram of Divigel® contains 1 mg of estradiol. According to the Society of Obstetricians and Gynecologists of Canada, 95% of women experience menopause after the age of 45.4 Divigel® is an estrogen gel available by prescription that has been proven to reduce both the frequency and severity of hot flashes and other vasomotor symptoms associated with menopause. Full details regarding the product’s clinical and safety evidence can be reviewed in the product monograph that is available online on the Health Canada Drug Product Database.3
About Searchlight Pharma
Searchlight Pharma Inc., headquartered in Montreal, aspires to become a leading Canadian-based specialty healthcare company through best-in class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. With a core focus on women’s health, urogynecology and urology, our team is committed to improving people’s lives by bringing the right products to market. Follow us, learn more about what we do, and get to know our product portfolio at www.searchlightpharma.com.
SOURCE Searchlight Pharma Inc.